Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157 (CROSBI ID 177771)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Sikirić, Predrag ; Seiwerth, Sven ; Ručman, Rudolf ; Turković, Branko ; Stančić-Rokotov, Dinko ; Brčić, Luka ; Sever, Marko ; Kliček, Robert ; Radić, Božo ; Drmić, Domagoj et al. Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157 // Current medicinal chemistry, 19 (2012), 1; 126-132. doi: 10.2174/092986712803414015

Podaci o odgovornosti

Sikirić, Predrag ; Seiwerth, Sven ; Ručman, Rudolf ; Turković, Branko ; Stančić-Rokotov, Dinko ; Brčić, Luka ; Sever, Marko ; Kliček, Robert ; Radić, Božo ; Drmić, Domagoj ; Ilić, Spomenko ; Kolenc, Danijela ; Stambolija, Vasilije ; Zoričić, Zoran ; Vrčić, Hrvoje ; Šebečić, Božidar

engleski

Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157

Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157’s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis

BPC 157; intestinal anastomosis; short bowel; colocutaneous fistulas; inflammatory bowel disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

19 (1)

2012.

126-132

objavljeno

0929-8673

10.2174/092986712803414015

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost